David Lebovitz
Stock Analyst at Citigroup
(3.20)
# 1,145
Out of 4,761 analysts
92
Total ratings
64.52%
Success rate
7.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $81 → $82 | $68.25 | +20.15% | 3 | Feb 20, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $37.46 | +97.54% | 2 | Nov 14, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $382 → $371 | $336.23 | +10.34% | 3 | Aug 8, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $291 → $342 | $250.59 | +36.48% | 30 | Aug 2, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $52.45 | -27.55% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $50.69 | -66.46% | 5 | Oct 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $111 → $92 | $92.25 | -0.27% | 6 | Feb 1, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $56.07 | -3.69% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $32.32 | +8.29% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $2.76 | +515.94% | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $1.82 | +506.06% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $152.43 | +30.55% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $34 → $32 | $0.60 | +5,247.59% | 2 | Nov 3, 2020 |
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Neutral
Price Target: $81 → $82
Current: $68.25
Upside: +20.15%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $37.46
Upside: +97.54%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Buy
Price Target: $382 → $371
Current: $336.23
Upside: +10.34%
Alnylam Pharmaceuticals
Aug 2, 2024
Maintains: Buy
Price Target: $291 → $342
Current: $250.59
Upside: +36.48%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $52.45
Upside: -27.55%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $50.69
Upside: -66.46%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111 → $92
Current: $92.25
Upside: -0.27%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $56.07
Upside: -3.69%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $32.32
Upside: +8.29%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $2.76
Upside: +515.94%
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $1.82
Upside: +506.06%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $152.43
Upside: +30.55%
Nov 3, 2020
Maintains: Overweight
Price Target: $34 → $32
Current: $0.60
Upside: +5,247.59%